Although preliminary data are encouraging, especially regarding the reduction of inflammation and body weight, open questions remain regarding the effects of these drugs on a longer time scale and on different patient subgroups
Providers need to show where medicines come from and how refills are managed
stratifying by metabolic status, by genetic risk such as GBA and LRRK2 variants in Parkinsons or APOE in Alzheimers, by disease stage, and potentially by GLP-1R polymorphism is the most plausible route to a positive trial
Some, like live vaccines, should not be mixed with it due to potential interactions with the bacteriostat
doi: 10.1007/s00210-021-02161-8 160
It covers glutathione and the full IV nutrient toolkit: biochemistry, dosing, IV-push technique, compounding and compliance, patient selection, safety, and honest benefit communication